Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?

BACKGROUND: Glioblastoma (GBM) is the most common malignant brain tumor with median survival of 12-15 months. Owing to uncertainty in clinical outcome, additional prognostic marker(s) apart from existing markers are needed. Since overexpression of endothelin B receptor (ETBR) has been demonstrated i...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasaikar, Suhas, Tsipras, Giorgos, Landázuri, Natalia, Costa, Helena, Wilhelmi, Vanessa, Scicluna, Patrick, Cui, Huanhuan L., Mohammad, Abdul-Aleem, Davoudi, Belghis, Shang, Mingmei, Ananthaseshan, Sharan, Strååt, Klas, Stragliotto, Giuseppe, Rahbar, Afsar, Wong, Kum Thong, Tegner, Jesper, Yaiw, Koon-Chu, Söderberg-Naucler, Cecilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801893/
https://www.ncbi.nlm.nih.gov/pubmed/29409474
http://dx.doi.org/10.1186/s12885-018-4012-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801893/
https://www.ncbi.nlm.nih.gov/pubmed/29409474
http://dx.doi.org/10.1186/s12885-018-4012-7

Ejemplares similares